FDA Requires Boxed Warning for Singulair, Generics

The US Food and Drug Administration (FDA) on Wednesday said it is requiring a boxed warning and medication guide for Merck’s asthma and allergy drug Singulair (montelukast) and its generics to strengthen existing warnings about the risk of neuropsychiatric events, including suicides, linked to the drug.